The Oncology Institute, Inc. (TOI) Insider Trading Activity

NASDAQ$3.41
Market Cap
$335.48M
Sector
Healthcare
Industry
Medical—Care Facilities
Rank in Sector
124 of 881
Rank in Industry
5 of 39

TOI Insider Trading Activity

TOI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,646,221
8
50
Sells
$34,421,673
8
50

Related Transactions

BARASCH RICHARD Adirector
1
$1.42M
0
$0
$1.42M
Pacala Mark Ldirector
1
$94,338
1
$200,000
$-105,662
Hively Braddirector
1
$47,168
3
$5.8M
$-5.76M
Johnson Karen Mariedirector
1
$37,735
0
$0
$37,735
Virnich DanielChief Executive Officer
1
$23,584
0
$0
$23,584
Castle JeremyChief Operating Officer
1
$9,434
0
$0
$9,434
Podnos YaleChief Medical Officer
1
$9,434
0
$0
$9,434
Carter Robert RossChief Financial Officer
1
$9,434
1
$879
$8,554
M33 Growth I L.P.
0
$0
3
$28.42M
$-28.42M

About The Oncology Institute, Inc.

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

Insider Activity of The Oncology Institute, Inc.

Over the last 12 months, insiders at The Oncology Institute, Inc. have bought $1.65M and sold $34.42M worth of The Oncology Institute, Inc. stock.

On average, over the past 5 years, insiders at The Oncology Institute, Inc. have bought $402,489 and sold $19.5M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BARASCH RICHARD A (director) — $1.42M. Pacala Mark L (director) — $94,338. Hively Brad (director) — $47,168.

The last purchase of 9,056 shares for transaction amount of $9,434 was made by Carter Robert Ross (Chief Financial Officer) on 2025‑03‑26.

List of Insider Buy and Sell Transactions, The Oncology Institute, Inc.

2026-01-02SaleCarter Robert RossChief Financial Officer
247
0.0003%
$3.56
$879
-22.75%
2025-12-15SaleHively Braddirector
13,333
0.0135%
$3.77
$50,291
-20.42%
2025-11-18SalePacala Mark Ldirector
50,000
0.0539%
$4.00
$200,000
-16.98%
2025-09-04SaleM33 Growth I L.P.
6.7M
6.7925%
$3.09
$20.7M
+3.22%
2025-08-19SaleHively Braddirector
20,221
0.023%
$4.06
$82,097
-11.52%
2025-06-05SaleM33 Growth I L.P.
750,000
0.9192%
$3.05
$2.29M
+20.97%
2025-06-03SaleHively Braddirector
1.98M
1.9873%
$2.87
$5.67M
+5.16%
2025-05-20SaleM33 Growth I L.P.
2M
2.1882%
$2.71
$5.43M
+19.78%
2025-03-26PurchaseBARASCH RICHARD Adirector
1.36M
1.5478%
$1.04
$1.42M
+164.46%
2025-03-26PurchaseVirnich DanielChief Executive Officer
22,640
0.0258%
$1.04
$23,584
+164.46%
2025-03-26PurchaseHively Braddirector
45,280
0.0516%
$1.04
$47,168
+164.46%
2025-03-26PurchasePacala Mark Ldirector
90,562
0.1032%
$1.04
$94,338
+164.46%
2025-03-26PurchaseJohnson Karen Mariedirector
36,224
0.0413%
$1.04
$37,735
+164.46%
2025-03-26PurchaseCastle JeremyChief Operating Officer
9,056
0.0103%
$1.04
$9,434
+164.46%
2025-03-26PurchasePodnos YaleChief Medical Officer
9,056
0.0103%
$1.04
$9,434
+164.46%
2025-03-26PurchaseCarter Robert RossChief Financial Officer
9,056
0.0103%
$1.04
$9,434
+164.46%
2024-12-02PurchaseHively Braddirector
50,000
0.065%
$0.15
$7,500
+1687.78%
2024-11-26PurchaseHively Braddirector
250,000
0.3151%
$0.17
$42,500
+1461.41%
2024-01-29SaleHavencrest Healthcare Partners, L.P.10 percent owner
8,637
0.0114%
$2.12
$18,310
-78.62%
2024-01-26SaleHavencrest Healthcare Partners, L.P.10 percent owner
6,979
0.0096%
$2.14
$14,935
-78.34%
Total: 114
*Gray background shows transactions not older than one year

Insider Historical Profitability

379.96%
BARASCH RICHARD Adirector
1775641
1.8049%
$6.05M60
+59.64%
Virnich DanielChief Executive Officer
724363
0.7363%
$2.47M11
Hively Braddirector
683721
0.695%
$2.33M36
+1574.6%
M33 Growth I L.P.
590892
0.6006%
$2.01M03
Carter Robert RossChief Financial Officer
235122
0.239%
$801,766.0211
Johnson Karen Mariedirector
203409
0.2068%
$693,624.6910
Pacala Mark Ldirector
174971
0.1778%
$596,651.1111
Castle JeremyChief Operating Officer
90386
0.0919%
$308,216.2610
Podnos YaleChief Medical Officer
79049
0.0803%
$269,557.0911
TOI HC I, LLCdirector
14423060
14.6604%
$49.18M018
Shah MihirChief Financial Officer
328122
0.3335%
$1.12M10
<0.0001%
Jimmy Holdings, Inc.
253436
0.2576%
$864,216.7601
Agajanian Richy10 percent owner
253436
0.2576%
$864,216.7601
Miller Matthew PChief Operating Officer
175325
0.1782%
$597,858.2511
+30.68%
Simoneit DionaChief Accounting Officer
29318
0.0298%
$99,974.3801
Kaushal Mohitdirector
25534
0.026%
$87,070.9402
Havencrest Healthcare Partners, L.P.10 percent owner
0
0%
$0060
*Gray background shows insiders who have made transactions during last year

TOI Institutional Investors: Active Positions

Increased Positions77+74.76%9M+25.07%
Decreased Positions44-42.72%5M-13.08%
New Positions30New2MNew
Sold Out Positions18Sold Out1MSold Out
Total Postitions136+32.04%39M+11.99%

TOI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$16,681.004.64%4.55M+264,358+6.17%2025-09-30
Blackrock, Inc.$12,606.003.51%3.43M+127,971+3.87%2025-09-30
Deerfield Management Company, L.P.$12,331.003.43%3.36M00%2025-09-30
Centerbook Partners Lp$9,926.002.76%2.7M+2M+277.8%2025-09-30
Balyasny Asset Management L.P.$9,242.002.57%2.52M00%2025-09-30
Kanen Wealth Management Llc$6,761.001.88%1.84M+2MNew2025-09-30
Wexford Capital Lp$5,766.001.6%1.57M+452,390+40.44%2025-09-30
Geode Capital Management, Llc$5,145.001.43%1.4M+122,463+9.57%2025-09-30
State Street Corp$4,147.001.15%1.13M+483,768+74.86%2025-09-30
Ubs Group Ag$3,875.001.08%1.06M+635,489+151.17%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.